Trial Profile

A Randomized, Observer-blinded, Dose Response Phase 2 Trial to Assess the Safety and Immunogenicity of Two Different Dose Levels of a Live-attenuated Chikungunya Virus Vaccine Candidate (VLA1553) in Healthy Children Aged 1 to 11 Years

Status: Active, no longer recruiting

Phase of Trial: Phase II

Latest Information Update: 11 Jun 2025

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs VLA 1553 (Primary) ; Meningococcal vaccine groups A B C Y W-135 conjugate
Indications Chikungunya virus infections
Focus Adverse reactions
Sponsors Valneva

05 Jun 2025 According to a Valneva media release, the trial is intended to support a pivotal Phase 3 study in children, which the Company expects to initiate in the first quarter of 2026,
05 Jun 2025 Results presented in the Valneva Media Release.
22 Jan 2025 Results presented in the Valneva Media Release.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com